In general, non-interchangeable FoB’s—which is what all of NVS’ FoB’s are—are not going to be big-selling drugs. That’s the whole premise of what MNTA is trying to accomplish with BAX.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”